People in France who have received a first dose of the COVID-19 vaccine from AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) may be offered an alternative vaccine for their second shot, Reuters news agency reported on Friday.
Health Minister Olivier Veran told RTL radio that he expected the French national health authority, Haute Autorité de santé (HAS), to recommend that recipients of a first dose of AstraZeneca's traditional COVID-19 vaccine who are under the age of 55 should get a second shot with a messenger-RNA (mRNA) vaccine.
Two mRNA vaccines, one made by Pfizer (NYSE:PFE) and its German partner BioNTech and another from Moderna Inc (Nasdaq:MRNA), are approved for use in France.
There are some concerns about a potentially higher risk of rare blood clots among younger people who have had the AstraZeneca vaccine.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients